Vitamin D is not really a vitamin but a hormone, made in the skin in sunlight and acting on receptors found in nearly every cell, including immune cells and many cancer cells. Low vitamin D levels have long been linked with higher cancer death rates, but the question that matters is whether taking vitamin D changes outcomes. The answer that emerged from the largest analysis, led by the German Cancer Research Center in Heidelberg, is more specific than most people realize: it depends on how vitamin D is taken.
How Vitamin D May Act on Cancer
In laboratory studies, the active form of vitamin D slows cancer cell growth, encourages abnormal cells to mature, and restrains new blood vessel growth. Its effects on the immune system may matter even more: it supports the function of immune cells that recognize and kill cancer cells and helps regulate inflammation.
The German Analysis: Daily Dosing Matters
Researchers at the German Cancer Research Center, led by the epidemiologist Hermann Brenner, combined all 14 randomized, placebo-controlled trials of vitamin D3 that reported cancer deaths, including the individual data of the participants. Across all trials together, vitamin D3 lowered cancer mortality by 6 percent, a difference that was not statistically significant. But the trials had given vitamin D in two very different ways. In the 10 trials in which vitamin D3 was taken daily, cancer mortality was 12 percent lower than with placebo. In the four trials that gave large doses weeks or months apart, there was no benefit at all. People aged 70 and older appeared to benefit most.1
The researchers concluded that vitamin D3 probably does not prevent cancer from developing, but that daily supplementation may reduce the likelihood of dying from it.
The Major Trials
VITAL (United States). In this trial of more than 25,000 adults, a daily vitamin D3 supplement did not reduce the number of people who developed cancer. Analyses that set aside the first years of the trial suggested fewer cancer deaths, a finding consistent with the German analysis.2
AMATERASU (Japan). In this randomized trial in patients who had surgery for cancers of the digestive tract, daily vitamin D3 did not significantly improve relapse-free survival overall. Later analyses suggested benefit in particular subgroups of patients, which needs confirmation.3
Lymphoma (Germany). In patients with diffuse large B-cell lymphoma, the German High-Grade Non-Hodgkin’s Lymphoma Study Group found that vitamin D deficiency was linked to worse outcomes with rituximab and weakened rituximab’s ability to direct immune cells against lymphoma.4 See our article on lymphoma treatment.
Using Vitamin D Wisely
Measure the level. A simple blood test for 25-hydroxyvitamin D shows whether a person is deficient and guides the amount needed. Many people with cancer are deficient.
Daily rather than large occasional doses. The German analysis is the strongest argument yet for regular daily intake over large intermittent doses.
Too much is harmful. Excess vitamin D raises blood calcium, which can cause kidney stones, kidney damage, confusion and heart rhythm problems. Levels should be rechecked once supplementation starts.
Special cautions. Some lymphomas and granulomatous diseases such as sarcoidosis produce extra active vitamin D on their own, so supplementation can push calcium dangerously high. Thiazide diuretics also raise calcium.
Vitamin D is one part of the terrain that influences how cancer behaves, alongside metabolism, inflammation, exercise and sleep. Our book, The New Reality of Cancer, covers vitamins and minerals in cancer in detail, and our article on colon cancer treatment describes the exercise trial that improved survival.
Frequently Asked Questions
Does vitamin D prevent cancer?
The trials suggest it probably does not prevent cancer from developing, but daily vitamin D3 was associated with a 12 percent reduction in cancer deaths in the German Cancer Research Center analysis.
Is daily vitamin D better than weekly or monthly doses?
In the analysis of all randomized trials, daily dosing reduced cancer mortality while large intermittent doses showed no benefit.
Can you take too much vitamin D?
Yes. Excess raises blood calcium and can damage the kidneys. Blood levels should guide supplementation.
Should vitamin D be checked during cancer treatment?
Measuring the 25-hydroxyvitamin D level is simple, and in lymphoma treated with rituximab, German research linked deficiency with worse outcomes.
About the author. Dr. Silver, MD, graduated from Temple University School of Medicine, trained as an interventional cardiologist, and has practiced medicine for nearly fifty years. A lymphoma survivor of about twenty-five years, he is co-author, with Dr. Lindmeier, DHSc, of The New Reality of Cancer: The Science of Recovery. Read more about Dr. Silver, MD.
Research by Dr. Lindmeier, DHSc, cancer educator and co-author of The New Reality of Cancer.
This article is for general education only and is not individual medical advice. Always consult your own doctor before making any changes to your care.
© 2026 Cancer Expert MD, Dr. Silver, MD, and Dr. Lindmeier, DHSc. All rights reserved. This article draws on the research in The New Reality of Cancer and may not be copied, republished or distributed without written permission.
For more in-depth information on this topic and many others, get our book, The New Reality of Cancer: The Science of Recovery.
More articles on integrative cancer treatments and all articles.
References
- Kuznia S, Zhu A, Akutsu T, et al. Efficacy of vitamin D3 supplementation on cancer mortality: systematic review and individual patient data meta-analysis of randomised controlled trials. Ageing Research Reviews. 2023;87:101923.
- Manson JE, Cook NR, Lee IM, et al. Vitamin D supplements and prevention of cancer and cardiovascular disease (VITAL). New England Journal of Medicine. 2019;380(1):33–44.
- Urashima M, Ohdaira H, Akutsu T, et al. Effect of vitamin D supplementation on relapse-free survival among patients with digestive tract cancers: the AMATERASU randomized clinical trial. JAMA. 2019;321(14):1361–1369.
- Bittenbring JT, Neumann F, Altmann B, et al. Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab. Journal of Clinical Oncology. 2014;32(29):3242–3248.
This article is for education only. It is not medical advice and does not diagnose or treat any condition. Cancer Expert MD has no financial relationship with any laboratory, drug maker, supplement company, clinic or hospital.
Responses
[…] dark bedroom, little screen light late at night, and a regular sleep schedule. See our articles on vitamin D and cancer and the guide to repurposed […]
[…] In the Japanese AMATERASU trial of people with digestive tract cancers, vitamin D after surgery did not improve relapse-free survival in the trial as a whole, but people whose tumors carried a particular p53 pattern did have fewer relapses.8 See our article on vitamin D. […]